Sequana Medical NV Net Assets
Sequana Medical NV net assets. Based on the latest financial reports, Sequana Medical NV (SEQUA) has net assets worth €-39.17 Million EUR (≈ $-45.80 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€14.57 Million ≈ $17.04 Million USD) and total liabilities (€53.74 Million ≈ $62.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Sequana Medical NV equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-39.17 Million |
| % of Total Assets | -268.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | -39456.34% |
| 10-Year Change | N/A |
| Growth Volatility | 329.61 |
Net Assets of Sequana Medical NV (2014–2024)
Net assets of Sequana Medical NV from 2014 to 2024. This chart illustrates how Sequana Medical NV's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Sequana Medical NV to measure how much of total assets are equity-financed.
Annual Net Assets for Sequana Medical NV (2014–2024)
The table below shows the annual net assets of Sequana Medical NV from 2014 to 2024. For live market cap and overall valuation, see Sequana Medical NV (SEQUA) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-44.38 Million ≈ $-51.88 Million |
-127.99% |
| 2023-12-31 | €-19.47 Million ≈ $-22.76 Million |
-803.99% |
| 2022-12-31 | €-2.15 Million ≈ $-2.52 Million |
-173.63% |
| 2021-12-31 | €-786.92K ≈ $-919.99K |
-797.86% |
| 2020-12-31 | €112.76K ≈ $131.83K |
-87.82% |
| 2019-12-31 | €925.93K ≈ $1.08 Million |
+104.94% |
| 2018-12-31 | €-18.76 Million ≈ $-21.93 Million |
-306.88% |
| 2017-12-31 | €-4.61 Million ≈ $-5.39 Million |
+30.85% |
| 2016-12-31 | €-6.67 Million ≈ $-7.80 Million |
-2242.31% |
| 2015-12-31 | €-284.66K ≈ $-332.79K |
-109.99% |
| 2014-12-31 | €2.85 Million ≈ $3.33 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sequana Medical NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20873151440.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Sequana Medical NV Net Assets Breakdown (December 2024)
Sequana Medical NV net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €4.60 Million | % |
| Other Comprehensive Income | €849.00K | % |
| Other Components | €200.84 Million | % |
| Total Equity | €-44.38 Million | 100.00% |
Sequana Medical NV Competitors by Market Cap
The table below lists competitors of Sequana Medical NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NexMetals Mining Corp. Common Shares
NASDAQ:NEXM
|
$47.77 Million |
|
Ene Technology Inc
TW:6243
|
$47.78 Million |
|
Clene Inc.
NASDAQ:CLNN
|
$47.80 Million |
|
Manomay Tex India Limited
NSE:MANOMAY
|
$47.80 Million |
|
Helium Evolution Inc
V:HEVI
|
$47.72 Million |
|
Inter Industries
TA:ININ
|
$47.69 Million |
|
Etherstack Plc
AU:ESK
|
$47.67 Million |
|
One and One Green Technologies. Inc Class A Ordinary Shares
NASDAQ:YDDL
|
$47.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sequana Medical NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -19,465,174 to -44,379,000, a change of -24,913,826.
- Net loss of 44,654,000 reduced equity.
- New share issuances of 11,665,400 increased equity.
- Other comprehensive income increased equity by 2,862,931.
- Other factors increased equity by 5,211,843.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-44.65 Million | -100.62% |
| Share Issuances | €11.67 Million | +26.29% |
| Other Comprehensive Income | €2.86 Million | +6.45% |
| Other Changes | €5.21 Million | +11.74% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Sequana Medical NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | €-0.02 | €0.61 | x |
| 2016-12-31 | €-0.49 | €0.61 | x |
| 2017-12-31 | €-0.34 | €0.61 | x |
| 2018-12-31 | €-1.37 | €0.61 | x |
| 2019-12-31 | €0.08 | €0.61 | x |
| 2020-12-31 | €0.01 | €0.61 | x |
| 2021-12-31 | €-0.04 | €0.61 | x |
| 2022-12-31 | €-0.09 | €0.61 | x |
| 2023-12-31 | €-0.73 | €0.61 | x |
| 2024-12-31 | €-1.21 | €0.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sequana Medical NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42126.42%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1856.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | -685.89% | 0.36x | 0.00x | €-11.53 Million |
| 2016 | 0.00% | -938.67% | 0.39x | 0.00x | €-13.31 Million |
| 2017 | 0.00% | -630.78% | 0.37x | 0.00x | €-7.76 Million |
| 2018 | 0.00% | -1358.69% | 0.31x | 0.00x | €-12.11 Million |
| 2019 | -1617.55% | -1543.05% | 0.10x | 10.10x | €-15.07 Million |
| 2020 | -16943.83% | -1983.45% | 0.07x | 126.05x | €-19.12 Million |
| 2021 | 0.00% | -6373.84% | 0.03x | 0.00x | €-23.54 Million |
| 2022 | 0.00% | -3334.08% | 0.04x | 0.00x | €-30.55 Million |
| 2023 | 0.00% | -4572.42% | 0.07x | 0.00x | €-30.62 Million |
| 2024 | 0.00% | -42126.42% | 0.01x | 0.00x | €-40.22 Million |
Industry Comparison
This section compares Sequana Medical NV's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $110,900,000
- Average return on equity (ROE) among peers: 8.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sequana Medical NV (SEQUA) | €-39.17 Million | 0.00% | N/A | $47.76 Million |
| Ion Beam Applications SA (IBAB) | $110.90 Million | 8.39% | 4.56x | $466.24 Million |
About Sequana Medical NV
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid over… Read more